Aytu BioPharma, Inc.

AYTU

Healthcare Drug Manufacturers Specialty & Generic

Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025.

Revenue
+6.42%
EPS
+100.0%
Free cash flow
+57.7%
Total debt
−21.9%

Quarter to June 2026, against a year earlier

1.83 0.02 +1.10%
Market cap
$19.9M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
3/9
ROIC
−20.0%
Net debt / EBITDA
2.2×
Dividend safety
n/a

Aytu BioPharma, Inc. (AYTU) P/E ratio

Alert me on P/E ratio

Aytu BioPharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 13.0× (May 2025) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2026 0.0× —
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
42 more quarters

Against its own ten years

Low 0.0× High 13.0×
Ten-year median 0.0×
Current reading's percentile 91

P/E ratio against peers

Company P/E ratio
CPHI China Pharma Holdings, Inc. compare n/m
SCYX SCYNEXIS, Inc. compare n/m
TXMD TherapeuticsMD, Inc. compare n/m
SHPH Shuttle Pharmaceuticals Holdings, Inc. compare n/m
IXHL Incannex Healthcare Inc. compare n/m
BFRI Biofrontera Inc. compare n/m
AYTU Aytu BioPharma, Inc. n/m
RMTI Rockwell Medical, Inc. compare n/m
OPTH Optimi Health Corp. compare —
Drug Manufacturers Specialty & Generic industry median 20.5×
Healthcare sector median 24.5×
Market median 17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on AYTU